Tag Archive for: Adherex

Adherex Selects Brian Huber As Chief Scientific Officer

Life Science Partner connects accomplished research executive with cancer therapeutics company

Life Science Partner announces the placement of Brian E. Huber, Ph.D., as chief scientific officer (CSO) at Adherex Technologies, Inc., in Research Triangle Park, North Carolina. As CSO, Huber will lead a 20-person research and development team focused on the preclinical development of compounds.

He and his team will provide scientific intelligence and guide decisions about potential clinical effectiveness and regulatory strategies. A biopharmaceutical company, Adherex discovers and develops cancer therapeutics through its pioneering platform for tumor vascular targeting.

“Brian’s a prime example of a scientist who thrived after his original transition from academia. In the ’90s, he was at Glaxo, which was known for its modern, innovative research organization,” says Thomas H. Callaway, Life Science Partner’s founder and president. “During that time, he demonstrated great entrepreneurial instincts and an ability to build high-performance drug development infrastructures. Adherex’s broad oncology pipeline should benefit from his work.”

A successful manager, Huber has managed multiple departments and large staffs at one of the largest pharmaceutical companies in the world. As a researcher who has secured many patents, he has contributed extensively to the literature and has frequently lectured at and organized symposia.

Huber comes to Adherex from GlaxoSmithKline where, most recently, he held the position of vice president of biology and pharmacology drug discovery. In this role, he was accountable for seven departments with total staff numbering 170, held therapeutic responsibility in more than a dozen areas, managed the portfolio from strategy through target selection and preclinical development, and chaired both joint ventures and major strategic alliances.

Under Glaxo Wellcome, he was director, and more recently vice president of the division of pharmacology with responsibility for the departments of cancer biology, rheumatic diseases, the metabolic diseases and virology.

Learn More About Life Science Partner

Click button below to learn more about how we recruit Chief Executives:

Learn More About Chief Executive Functions
/0 Comments/by

Rajesh Malik Chosen To Lead Clinical Development – Adherex

Life Science Partner places pharmaceutical veteran and oncology specialist as chief medical officer

ATLANTA, Georgia – September 7, 2004 – Life Science Partner announces the placement of Rajesh K. Malik, M.B., Ch.B. as chief medical officer at Adherex Technologies, Inc., in Research Triangle Park, North Carolina. With the position, Malik takes responsibility for the clinical development efforts behind Adherex’s growing portfolio of oncology products. He will

guide decisions about clinical utility, formulate regulatory strategies for the U.S. and Europe, lead the clinical trials design team, and promote physician advocacy. A biopharmaceutical company, Adherex discovers and develops cancer therapeutics through its pioneering platform for tumor vascular targeting.

“For Adherex, Raj was an exceptional find,” says Life Science Partner, Founder and President Thomas H. Callaway. “In addition to his original insights into anti-angiogenesis, which is at the core of Adherex’s product portfolio, he has a successful record of regulatory submission on three continents and he fully understands the commercialization process.”

A pediatric oncologist by training, Malik combines experience in cutting-edge academic research with strong business analytical skills and accomplishments in corporate pharmaceutical environments large and small.

Prior to Adherex, Malik was executive director at EMD Pharmaceuticals, a subsidiary of Germany-based Merck KGaA. As part of senior management at EMD, Malik led global project management for single oncology products and served on the company’s combined business and clinical operations team to guide global oncology product strategy.

As associate director at Bristol Myers Squibb, Malik held responsibility for the clinical development strategy for oral taxane worldwide and provided clinical oversight for Erbitux in Europe.

Malik also spent seven years as an assistant professor at the University of Virginia, where his research focused on signal transduction across the interface of integrins and extra cellular matrix.

Malik holds a medical degree from the School of Medicine and Biomedical Sciences at the University of Sheffield, Sheffield, U.K. He is licensed in pediatrics in North Carolina and Virginia.

/0 Comments/by

James Klein Selected by Adherex to Serve as CFO

Life Science Partner recruits pharma finance executive with entrepreneurial and global R&D experience

Life Science Partner announces the placement of James A. Klein, Jr., as chief financial officer at Adherex Technologies, Inc., to be based in its new Research Triangle Park, North Carolina headquarters. Klein assumes overall responsibility for the company’s financial health and integrity. He will oversee ongoing financing of this publicly traded company, including analysis and review of financial data, reporting performance, and internal operations.

A biopharmaceutical company, Adherex discovers and develops cancer therapeutics through its pioneering platform for tumor vascular targeting.

“James Klein’s broad, varied experience prepares him well for Adherex,” says Life Science Partner Founder and President Thomas H. Callaway. “On the one hand, he directed finance for a $500 million international research operation at Wellcome. On the other hand, he was the start-up CFO of an emerging pharma company. So he’s a proven quantity and a tremendous resource.”

To his experience in finance matters ranging from intellectual property to IPOs to cost controls, Klein adds a firm understanding of the drug development, research organizations, and business management. Klein transitions to Adherex from a company he founded, DataScout Software, which develops data acquisition and management solutions for the pharmaceutical industry.

Previously, Klein was an early employee of Triangle Pharmaceuticals, serving as CFO and treasurer. With Klein managing all financial aspects of the operation, Triangle raised venture capital and held a successful initial public offering.  With a market capitalization of more than $500 million at Triangle, Klein oversaw SEC filings, financial reporting, accounting, budgeting, long-range planning, risk management, as well as investor relations.

At Burroughs, Klein held the titles of international R&D financial controller, senior financial analyst, and various other corporate accounting positions. Here, he held financial responsibility for a $500 million, international R&D operation. In addition to financial reporting, Klein guided business plans for new product acquisitions; managed facilities expansions; and served as a member of the international integration committee during the Glaxo-Wellcome merger.

Klein earned his accounting degree at the University of Mississippi. He is a certified public accountant in the state of North Carolina.

/0 Comments/by